Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2019 | Pages:
100 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The global neurological biomarkers market size is expected to reach USD 16.5 billion by 2026, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 14.5% over the forecast period, driven by an increasing prevalence of neurological diseases and emergence of novel diagnostic products. Neurological biomarkers can be used for diagnostics, drug discovery, or personalized medicines among other applications. These products may be employed in drug development to reduce attrition rates during clinical trials. Some neurological biomarkers can further be used to predict drug failures early in the development process by determining their pharmacological effect on patients, which helps the pharmaceutical company obviate additional costs associated with further clinical trials. There remains a significant dearth for in-depth knowledge of the pathophysiologies of several neurological disorders, thus resonating with the unmet need for more research and increased funding for the same. Though technological advancements and rising consumer awareness are flag-bearers in this market growth, there remains considerable scope for advanced diagnostics - in terms of precision, specificity, and test time. The diagnostic landscape in this market is gradually shifting towards genetic testing and counseling. Biomarker signatures are a rising trend in the diagnosis and treatment of neurological diseases. This has resulted in non-invasive testing, faster drug development, and early diagnosis of abnormalities/diseases. Furthermore, digital biomarkers provide various pharmaceutical companies with contextual and supplemental information to conclude clinical trial decisions. For instance, IXICO plc is collaborating with biopharmaceutical companies to validate clinically digital biomarkers and use them in clinical trials. Proactive initiatives by public and private organizations to heighten consumer awareness is a key driver of the neurological biomarkers market. For instance, the National Alliance on Mental Illness (NAMI) one of the largest grassroot organizations in the U.S. is dedicated to educating, advocating, and supporting mental health patients about diagnosis and apt treatment for their conditions. Such drivers reflect a prosperous future in the global biomarkers market. Further key findings from the report suggest: • Most biomarkers evaluating neuronal damage cannot be clinically useful individually, and are generally used in panels • Most cerebrospinal fluid biomarkers used in medical practice are amyloid ? and tau proteins • Nascent products allow a broader scope for characterization and selection of treatment strategies • Inconsistent regulatory trends remain a major constraint for the market • Asia Pacific is positioned to witness the fastest regional growth
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR's internal database
1.3.3. Secondary sources & third-party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Global Neurological Biomarkers Market Variables, Trends & Scope
3.1. Neurological Biomarkers Market Lineage outlook
3.1.1. Parent market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Pipeline Analysis
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of neurological diseases
3.4.1.2. Technological advancements
3.4.1.3. Increased funding for R&D in biomarkers
3.4.2. Market restraint analysis
3.4.2.1. Lack of consumer awareness
3.4.2.2. Reimbursement policies
3.5. Neurological Biomarkers Market Analysis Tools
3.5.1. Industry analysis - Porter's
3.5.1.1. Supplier Power: High due to large number of diagnostic test manufacturers
3.5.1.2. Buyer Power: Moderate due to long-term contract with manufacturers
3.5.1.3. Substitution Threat: Moderate due to less/no external substitutes
3.5.1.4. Threat from New Entrant: Moderate due to limited number of new players
3.5.1.5. Competitive Rivalry: High due to increasing mergers & acquisitions by players
3.5.2. PESTEL Analysis
3.5.2.1. Political Landscape
3.5.2.2. Environmental Landscape
3.5.2.3. Social Landscape
3.5.2.4. Technology Landscape
3.5.2.5. Legal Landscape
Chapter 4. Neurological Biomarkers Market: Application Estimates & Trend Analysis
4.1. Definitions & Scope
4.2. Application Market Share Analysis, 2018 & 2026
4.3. Application Dashboard
4.4. Global Neurological Biomarkers Market, By Application, 2015 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
4.5.1. Alzheimer's disease
4.5.1.1. Alzheimer's disease market, 2015 - 2026 (USD Million)
4.5.2. Parkinson's disease
4.5.2.1. Parkinson's disease market, 2015 - 2026 (USD Million)
4.5.3. Multiple sclerosis
4.5.3.1. Multiple sclerosis market, 2015 - 2026 (USD Million)
4.5.4. Autism spectrum disorders
4.5.4.1. Autism spectrum disorders market, 2015 - 2026 (USD Million)
4.5.5. Others
4.5.5.1. Others market, 2015 - 2026 (USD Million)
Chapter 5. Neurological Biomarkers Market: Type Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Type Market Share Analysis, 2018 & 2026
5.3. Type Dashboard
5.4. Global Neurological Biomarkers Market, By Type, 2015 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
5.5.1. Genomic
5.5.1.1. Genomic market, 2015 - 2026 (USD Million)
5.5.2. Proteomic
5.5.2.1. Proteomic market, 2015 - 2026 (USD Million)
5.5.3. Metabolomic
5.5.3.1. Metabolomic market, 2015 - 2026 (USD Million)
5.5.4. Imaging
5.5.4.1. Imaging market, 2015 - 2026 (USD Million)
5.5.5. Others
5.5.5.1. Others market, 2015 - 2026 (USD Million)
Chapter 6. Neurological Biomarkers Market: End-use Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. End-use Market Share Analysis, 2018 & 2026
6.3. End-use Dashboard
6.4. Global Neurological Biomarkers Market, By End-use, 2015 to 2026
6.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
6.5.1. Hospital laboratories
6.5.1.1. Hospital laboratories market, 2015 - 2026 (USD Million)
6.5.2. Independent clinical diagnostic centers
6.5.2.1. Independent clinical diagnostic centers, 2015 - 2026 (USD Million)
6.5.3. Research organizations
6.5.3.1. Research organizations, 2015 - 2026 (USD Million)
6.5.4. Others
6.5.4.1. Others, 2015 - 2026 (USD Million)
Chapter 7. Neurological Biomarkers Market: Regional Estimates & Trend analysis
7.1. Regional Market Snapshot
7.2. Regional Market Share and Leading Players, 2018
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
7.4.1. North America
7.4.1.1. North America neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.1.2. U.S.
7.4.1.2.1. U.S. neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.1.3. Canada
7.4.1.3.1. Canada neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.2. Europe
7.4.2.1. Europe neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.2.2. U.K.
7.4.2.2.1. U.K. neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.2.3. Germany
7.4.2.3.1. Germany neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.2.4. Spain
7.4.2.4.1. Spain neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.2.5. France
7.4.2.5.1. France neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.2.6. Italy
7.4.2.6.1. Italy neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.3. Asia Pacific
7.4.3.1. Asia Pacific neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.3.2. China
7.4.3.2.1. China neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.3.3. Japan
7.4.3.3.1. Japan neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.3.4. India
7.4.3.4.1. India neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.3.5. South Korea
7.4.3.5.1. South Korea neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.3.6. Australia
7.4.3.6.1. Australia neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.4. Latin America
7.4.4.1. Latin America neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.4.2. Brazil
7.4.4.2.1. Brazil neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.4.3. Mexico
7.4.4.3.1. Mexico neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.4.4. Argentina
7.4.4.4.1. Argentina neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.5. Middle East Africa
7.4.5.1. MEA neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.5.2. South Africa
7.4.5.2.1. South Africa neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.5.3. Saudi Arabia
7.4.5.3.1. Saudi Arabia neurological biomarkers market, 2015 - 2026 (USD Million)
7.4.5.4. UAE
7.4.5.4.1. UAE neurological biomarkers market, 2015 - 2026 (USD Million)
Chapter 8. Company Profiles
8.1. Recent developments & impact analysis, by key market participants
8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
8.3. Public Companies
8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
8.3.2. Competitive dashboard analysis
8.3.3. Market differentiators
8.4. Private Companies
8.5. Strategic Framework
8.6. Company Profiles
8.6.1. Abbott
8.6.1.1. Company overview
8.6.1.2. Financial performance
8.6.1.3. Product benchmarking
8.6.1.4. Strategic initiatives
8.6.2. QIAGEN
8.6.2.1. Company overview
8.6.2.2. Financial performance
8.6.2.3. Product benchmarking
8.6.2.4. Strategic initiatives
8.6.3. Myriad RBM
8.6.3.1. Company overview
8.6.3.2. Financial performance
8.6.3.3. Product benchmarking
8.6.3.4. Strategic initiatives
8.6.4. Thermo Fisher Scientific Inc.
8.6.4.1. Company overview
8.6.4.2. Financial performance
8.6.4.3. Product benchmarking
8.6.4.4. Strategic initiatives
8.6.5. Athena Diagnostics
8.6.5.1. Company overview
8.6.5.2. Financial performance
8.6.5.3. Product benchmarking
8.6.5.4. Strategic initiatives
8.6.6. Bio-Rad Laboratories, Inc.
8.6.6.1. Company overview
8.6.6.2. Financial performance
8.6.6.3. Product benchmarking
8.6.6.4. Strategic initiatives
8.6.7. AbaStar MDx, Inc.
8.6.7.1. Company overview
8.6.7.2. Financial performance
8.6.7.3. Product benchmarking
8.6.7.4. Strategic initiatives
8.6.8. Acumen Pharmaceuticals
8.6.8.1. Company overview
8.6.8.2. Financial performance
8.6.8.3. Product benchmarking
8.6.8.4. Strategic initiatives
8.6.9. BANYAN BIOMARKERS, INC.
8.6.9.1. Company overview
8.6.9.2. Financial performance
8.6.9.3. Product benchmarking
8.6.9.4. Strategic initiatives
8.6.10. Alseres Pharmaceuticals, Inc.
8.6.10.1. Company overview
8.6.10.2. Financial performance
8.6.10.3. Product benchmarking
8.6.10.4. Strategic initiatives
List of Tables TABLE 1 List of Abbreviation TABLE 2 North America neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 3 North America neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 4 North America neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 5 U.S. neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 6 U.S. neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 7 U.S. neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 8 Canada neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 9 Canada neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 10 Canada neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 11 Europe neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 12 Europe neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 13 Europe neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 14 U.K. neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 15 U.K. neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 16 U.K. neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 17 Germany neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 18 Germany neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 19 Germany neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 20 France neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 21 France neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 22 France neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 23 Italy neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 24 Italy neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 25 Italy neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 26 Spain neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 27 Spain neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 28 Spain neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 29 Asia Pacific neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 30 Asia Pacific neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 31 Asia Pacific neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 32 Japan neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 33 Japan neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 34 Japan neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 35 China neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 36 China neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 37 China neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 38 India neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 39 India neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 40 India neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 41 South Korea neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 42 South Korea neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 43 South Korea neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 44 Australia neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 45 Australia neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 46 Australia neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 47 Latin America neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 48 Latin America neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 49 Latin America neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 50 Brazil neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 51 Brazil neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 52 Brazil neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 53 Mexico neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 54 Mexico neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 55 Mexico neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 56 Argentina neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 57 Argentina neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 58 Argentina neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 59 MEA neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 60 MEA neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 61 MEA neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 62 South Africa neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 63 South Africa neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 64 South Africa neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 65 Saudi Arabia neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 66 Saudi Arabia neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 67 Saudi Arabia neurological biomarkers market, by end-use, 2015 - 2026 (USD Million) TABLE 68 UAE neurological biomarkers market, by application, 2015 - 2026 (USD Million) TABLE 69 UAE neurological biomarkers market, by type, 2015 - 2026 (USD Million) TABLE 70 UAE neurological biomarkers market, by end-use, 2015 - 2026 (USD Million)
List of Figures FIG. 1 Market research process FIG. 2 Information procurement FIG. 3 Market summary FIG. 4 Market segmentation & scope FIG. 5 Market size and growth prospects FIG. 6 Global neurological biomarkers market- Key market driver analysis FIG. 7 Global neurological biomarkers market - Key market restraint analysis FIG. 8 Penetration & growth prospect mapping FIG. 9 Global neurological biomarkers market - Porter's analysis FIG. 10 Global neurological biomarkers market - PESTEL analysis FIG. 11 Global neurological biomarkers market application outlook key takeaways FIG. 12 Global neurological biomarkers market: Application movement analysis FIG. 13 Alzheimer's disease market estimates, 2015 - 2026 (USD Million) FIG. 14 Parkinson's disease market estimates, 2015 - 2026 (USD Million) FIG. 15 Multiple sclerosis market estimates, 2015 - 2026 (USD Million) FIG. 16 Autism spectrum disorders market estimates, 2015 - 2026 (USD Million) FIG. 17 Others market estimates, 2015 - 2026 (USD Million) FIG. 18 Global neurological biomarkers market type outlook key takeaways FIG. 19 Global neurological biomarkers market: Type movement analysis FIG. 20 Genomic market estimates, 2015 - 2026 (USD Million) FIG. 21 Proteomic market estimates, 2015 - 2026 (USD Million) FIG. 22 Metabolomic market estimates, 2015 - 2026 (USD Million) FIG. 23 Imaging market estimates, 2015 - 2026 (USD Million) FIG. 24 Others market estimates, 2015 - 2026 (USD Million) FIG. 25 Global neurological biomarkers market end-use outlook key takeaways FIG. 26 Global neurological biomarkers market: End-use movement analysis FIG. 27 Hospital laboratories market estimates, 2015 - 2026 (USD Million) FIG. 28 Independent clinical diagnostic centers market estimates, 2015 - 2026 (USD Million) FIG. 29 Research organizations market estimates, 2015 - 2026 (USD Million) FIG. 30 Others market estimates, 2015 - 2026 (USD Million) FIG. 31 Regional marketplace: Key takeaways FIG. 32 Global neurological biomarkers market: Regional movement analysis FIG. 33 North America neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 34 U.S. neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 35 Canada neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 36 Europe neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 37 U.K. neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 38 Germany neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 39 France neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 40 Spain neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 41 Italy neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 42 Asia Pacific neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 43 Japan neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 44 China neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 45 India neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 46 South Korea neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 47 Australia neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 48 Latin America neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 49 Brazil neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 50 Mexico neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 51 Argentina neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 52 MEA neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 53 South Africa neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 54 Saudi Arabia neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 55 UAE neurological biomarkers market, 2015 - 2026 (USD Million) FIG. 56 Strategy framework
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
